P-glycoprotein: a clue to vitamin K antagonist stabilization
- Resource Type
- Authors
- Jules Alexandre Desmeules; Alain Matthey; Pascal Bonnabry; Victoria Rollason; Pierre Dayer; Michela Rebsamen; Liliane Gschwind; Françoise Boehlen; Christophe Combescure
- Source
- Pharmacogenomics, Vol. 16, No 2 (2015) pp. 129-36
- Subject
- Male
ATP Binding Cassette Transporter, Subfamily B
Vitamin K
Genotype
medicine.drug_class
Pharmacology
Therapeutic index
Thromboembolism
Genetics
medicine
Humans
International Normalized Ratio
Prospective Studies
ddc:613
ddc:616
ddc:615
Acenocoumarol
Polymorphism, Genetic
ddc:617
business.industry
Warfarin
Anticoagulants
Middle Aged
Vitamin K antagonist
Treatment Outcome
Molecular Medicine
Female
Gene polymorphism
business
Pharmacogenetics
Cohort study
medicine.drug
- Language
- ISSN
- 1744-8042
1462-2416
Background: Acenocoumarol is a vitamin K antagonist used in some European countries. As warfarin, this drug is characterized by a narrow therapeutic index and a large interindividual variability. Aim: The objective of this study was to assess the involvement of ABCB1 polymorphisms on acenocoumarol treatment. Materials & methods: An observational cohort study was conducted to assess whether there is an association between the presence of the allelic variants of the ABCB1 gene coding for P-glycoprotein and acenocoumarol stabilization and daily doses during the first 35 days of treatment. Results: One hundred and fifteen patients met the inclusion criteria. The results of the clinical study showed that carriers of ABCB1 c.3435TT were more rapidly stabilized than wild-type patients (HR: 2.97, 95% CI: 1.23–7.18; p = 0.02). The same tendency was observed for the ABCB1 c.2677GT and 2677TT genotypes compared with ABCB1 c.2677GG. The ABCB1 c.2677TT genotype was also associated with a significant increase in doses of acenocoumarol (p = 0.03), the same tendency was observed with the ABCB1 c.3435TT genotype compared with the wild-type patients. Conclusion: These data suggest that ABCB1 polymorphisms could be involved in the response to acenocoumarol treatment. Original submitted 6 June 2014; Revision submitted 5 November 2014